𝛼SK or Search

ENTITY

Myovant Sciences (MYOV US)

5

Analysis

Health Care • Japan

Myovant Sciences Ltd. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing innovative therapies for women's health diseases and other endocrine-related disorders. Myovant Sciences develops relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis-associated pain.

more

Refresh

Exchange Announcement • 20 Mar 2023 21:58

US SEC Form 15-12G for Myovant Sciences Ltd

Exchange Announcement • 10 Mar 2023 21:11

US SEC Form 25-NSE for Myovant Sciences Ltd

Exchange Announcement • 10 Mar 2023 17:32

Statement of changes in beneficial ownership of securities - general instructions (PDF)

Exchange Announcement • 10 Mar 2023 17:32

Statement of changes in beneficial ownership of securities - general instructions (PDF)

Exchange Announcement • 10 Mar 2023 17:31

Statement of changes in beneficial ownership of securities - general instructions (PDF)

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x